Treatment of idiopathic pulmonary fibrosis with an extracellular vesicle isolate product

Richard Bligh *

777 S New Ballas Rd, Suite 200 E, St Louis, MO 63141.
 
Review
International Journal of Science and Research Archive, 2021, 02(02), 231–236.
Article DOI: 10.30574/ijsra.2021.2.2.0060
Publication history: 
Received on 04 April 2021; revised on 19 May 2021; accepted on 22 May 2021
 
Abstract: 
Idiopathic Pulmonary Fibrosis (IPF) is associated with serious morbidity and mortality. Airway epithelial cell injury is important in IPF pathogenesis. Injured lung epithelial cells are a source of inflammatory mediators such as TNF-α, IL-1β, GM-CSF, TGFβ, and CXCL-8. Mesenchymal Stem Cells (MSCs) have many anti-inflammatory properties. The clinical efficacy of using mesenchymal stem cells for regenerative medicine is not dependent on the living cells but entirely on their paracrine release of growth factors (GFs) and Extracellular Vesicles (EVs). This a case report of a 74-year-old white male diagnosed with IPF. He had extreme SOB with even small amounts of exertion. CT scanning was consistent with IPF. He was treated with nebulized and IV XoFloTM, a bone marrow derived mesenchymal stem cell extracellular vesicle isolate acellular product. He experienced significant objective improvements with his IPF. His room O2 went from the high 70’s to the high 90’s with improved PFTs.
 
Keywords: 
Mesenchymal Stem Cells; Pulmonary Fibrosis; Extracellular vesicles; Exosomes
 
Full text article in PDF: 
 
Copyright information: 

Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0